Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P9-RI
- Development stage
- Preclinical
- Lead developer
- Oxalo Therapeutics
- Modality
- Peptides
- Administration
- Oral
01
Overview
P9-RI is a retro-inverso (RI) modified peptide derived from *Oxalobacter formigenes* (specifically from the Sel1-like protein OxBSel1-14). It is being developed by the University of Chicago and its spinout Oxalo Therapeutics for the treatment of hyperoxaluria, hyperoxalemia, and related calcium oxalate kidney stones. P9-RI is designed to be completely resistant to proteolytic degradation by enzymes such as trypsin, proteinase K, and colonic lavage fluid, while retaining the ability to stimulate intestinal oxalate transport. It acts by stimulating colonic oxalate secretion via the oxalate transporters SLC26A6 and SLC26A2 in a protein kinase A (PKA)-dependent pathway.
- Other names
- retro-inverso P9retro-inverso P9 peptideretroinverso P9
Beyond the preview
Go deeper on P9-RI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P9-RI.